Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen

Area of Science:

• Nuclear medicine
• Radiopharmaceutical therapy
• Oncology

Background:

• Auger electron emitters like Iodine-125 ((125)I) offer high linear energy transfer and short emission range, ideal for precise cancer treatment.
• Prostate-specific membrane antigen (PSMA) is a highly specific target for prostate cancer cells.

Purpose of the Study:

• To evaluate the efficacy of a PSMA-targeted Auger emitter, (125)I-DCIBzL, for prostate cancer treatment.
• To assess the specificity and in vivo antitumor activity of (125)I-DCIBzL.

Main Methods:

• Synthesis of the PSMA-targeting Auger emitter (125)I-DCIBzL.
• Assessment of DNA damage and clonogenic survival in PSMA-positive and PSMA-negative prostate cancer cells.
• In vivo evaluation of antitumor efficacy in mouse xenograft models.

Main Results:

• PSMA-positive cells showed increased DNA damage and reduced survival after (125)I-DCIBzL treatment compared to PSMA-negative cells.
• Significant tumor growth delay was observed in mice bearing PSMA-positive tumors treated with (125)I-DCIBzL.
• Confocal microscopy confirmed drug localization in the perinuclear area and plasma membrane.

Conclusions:

• PSMA-targeted radiopharmaceutical therapy with (125)I-DCIBzL demonstrates high specificity and potent antitumor efficacy in vivo.
• This approach holds significant promise for the treatment of prostate cancer, particularly for targeting micrometastases.